Faster Return to Intended Oncologic Treatment (RIOT) After Trisectionectomy Does Not Translate to Better Outcomes

Background Resection with trisectionectomy may necessitate liver molding for adequate future liver remnant (FLR), and subsequent complications can impact return to intended oncologic therapy (RIOT). This study evaluated whether a difference in RIOT exists with the use of molding and between liver molding techniques (associating liver partition and portal vein ligation for staged hepatectomy [ALPPS] and portal vein embolization [PVE]) with trisectionectomy. Methods A retrospective review evaluated trisectionectomies for malignancy. Outcomes were compared with and without molding, and RIOT was determined. Results Fifty-one patients underwent trisectionectomy: 11 ALPPS, 14 PVE, 26 without molding. 73% of ALPPS, 64% of PVE, and 58% without molding achieved RIOT (P = .971). There were no differences found in baseline characteristics, R0 rate, length of stay, readmission, complications, or mortality. Time to RIOT was significantly different (ALPPS: 3.3 months; PVE: 5.2 months; none: 2.4 months, P = .0203). There were no differences in recurrence or survival. Conclusions Liver molding should not cause apprehension as there are no differences in achieving RIOT. Although technique alters time to RIOT, this does not translate into improved outcomes, implicating disease biology, and regeneration stimulus.

[1]  Bradford J. Kim,et al.  Detours on the Road to Recovery: What Factors Delay Readiness to Return to Intended Oncologic Therapy (RIOT) After Liver Resection for Malignancy? , 2019, Journal of Gastrointestinal Surgery.

[2]  B. Isaksson,et al.  The impact of post-hepatectomy liver failure on mortality: a population-based study , 2018, Scandinavian journal of gastroenterology.

[3]  A. Schnitzbauer,et al.  The HPB controversy of the decade: 2007-2017 - Ten years of ALPPS. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  A. Schnitzbauer A Comparison of Pitfalls after ALPPS Stage 1 or Portal Vein Embolization in Small-for-Size Setting Hepatectomies , 2017, Visceral Medicine.

[5]  D. Watters,et al.  Systematic review and meta-analysis of hepatic resection versus transarterial chemoembolization for solitary large hepatocellular carcinoma. , 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[6]  W. Lau,et al.  Associating liver partition and portal vein ligation for staged hepatectomy: the current role and development. , 2017, Hepatobiliary & pancreatic diseases international : HBPD INT.

[7]  Bradford J. Kim,et al.  The Impact of Postoperative Complications on a Timely Return to Intended Oncologic Therapy (RIOT): the Role of Enhanced Recovery in the Cancer Journey , 2016, International anesthesiology clinics.

[8]  U. Neumann,et al.  The ALPPS Risk Score: Avoiding Futile Use of ALPPS , 2016, Annals of surgery.

[9]  Y. Koyama,et al.  Prediction of posthepatectomy liver failure based on liver stiffness measurement in patients with hepatocellular carcinoma. , 2016, Surgery.

[10]  A. Bartlett,et al.  A systematic review and meta-analysis of portal vein ligation versus portal vein embolization for elective liver resection. , 2015, Surgery.

[11]  U. Neumann,et al.  Role of surgery in cholangiocarcinoma: From resection to transplantation. , 2015, Best practice & research. Clinical gastroenterology.

[12]  P. Bachellier,et al.  Post-hepatectomy liver failure in patients with colorectal liver metastases , 2015, Surgery Today.

[13]  K. Bertens,et al.  ALPPS: challenging the concept of unresectability--a systematic review. , 2015, International journal of surgery.

[14]  A. White,et al.  Impact of Margin Status and Neoadjuvant Chemotherapy on Survival, Recurrence After Liver Resection for Colorectal Liver Metastasis , 2015, Annals of surgical oncology.

[15]  C. Tschuor,et al.  ALPPS: From Human to Mice Highlighting Accelerated and Novel Mechanisms of Liver Regeneration , 2014, Annals of surgery.

[16]  J. Vauthey,et al.  Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy , 2014, Journal of surgical oncology.

[17]  M. Tez,et al.  Role of surgery in colorectal cancer liver metastases. , 2014, World journal of gastroenterology.

[18]  A. Viste,et al.  Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival , 2014, World Journal of Surgical Oncology.

[19]  C. Tschuor,et al.  ALPPS Offers a Better Chance of Complete Resection in Patients with Primarily Unresectable Liver Tumors Compared with Conventional-Staged Hepatectomies: Results of a Multicenter Analysis , 2014, World Journal of Surgery.

[20]  S. Nadalin,et al.  Indications and Limits for Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS). Lessons Learned from 15 Cases at a Single Centre , 2014, Zeitschrift für Gastroenterologie.

[21]  MS MPhil Frcs Sanjay Pandanaboyana MBBS,et al.  Impact of Margin Status and Neoadjuvant Chemotherapy on Survival, Recurrence After Liver Resection for Colorectal Liver Metastasis , 2014, Annals of Surgical Oncology.

[22]  M. Donati,et al.  ALPPS for Patients with Colorectal Liver Metastases: Effective Liver Hypertrophy, but Early Tumor Recurrence , 2014, World Journal of Surgery.

[23]  G. Fürst,et al.  In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two‐stage liver resection , 2013, The British journal of surgery.

[24]  D. Gouma,et al.  Tumor Progression After Preoperative Portal Vein Embolization , 2012, Annals of surgery.

[25]  P. Bachellier,et al.  Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. , 2012, Annals of surgery.

[26]  R. Lilford,et al.  Efficacy of Adjuvant Chemotherapy after Surgery when Considered over all Cancer Types: A Synthesis of Meta-Analyses , 2012, Annals of Surgical Oncology.

[27]  P. Clavien,et al.  Playing Play-Doh to prevent postoperative liver failure: the "ALPPS" approach. , 2012, Annals of surgery.

[28]  A. Ruzzenente,et al.  How Much Remnant Is Enough in Liver Resection? , 2012, Digestive Surgery.

[29]  V. Pamecha,et al.  Effect of portal vein embolisation on the growth rate of colorectal liver metastases , 2009, British Journal of Cancer.

[30]  N. Petrelli Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[32]  N. Habib,et al.  Preoperative Portal Vein Embolization for Major Liver Resection: A Meta-Analysis , 2008, Annals of surgery.

[33]  T. Aikou,et al.  Acceleration of primary liver tumor growth rate in embolized hepatic lobe after portal vein embolization , 2007, Acta radiologica.

[34]  N. Kokudo,et al.  Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases , 1998, Annals of Surgical Oncology.

[35]  C. Köhne,et al.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Evelyne M. Loyer,et al.  Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases , 2005, Annals of surgery.

[37]  T. Muto,et al.  Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization , 2001, Hepatology.

[38]  T. de Baère,et al.  During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma , 1999, The British journal of surgery.

[39]  M. Makuuchi,et al.  Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. , 1990, Surgery.